Expanding the reach ofAntibody-Based Therapiesto more cancers,more diseases,more lives
A need for more effective treatment
Triple-negative breast cancer (TNBC) is among the most aggressive and devastating cancers. For patients with metastatic disease, outcomes remain dismal—only about 15% survive long term, and most live just 11–13 months after diagnosis. TNBC patients urgently need new, more effective treatment options
Our science
Targeted therapies to transform cancer treatment
Our patented antibody technology targets a cancer-specific marker, attacking tumors with precision while sparing healthy cells. By combining precision targeting with the flexibility to support multiple treatment formats, this distinctive platform is designed to deliver safer, more effective therapies for some of the most aggressive cancers.
Precision targeting
Patented design
Flexible payload options
Latest updates
December 17, 2025
Antigenix Therapeutics Emerges from Stealth with $7 Million Seed Financing to Advance Development of Novel Antibody-Drug Conjugate Therapies
Antigenix Therapeutics is coming out of Stealth with $7 million in seed funding to advance the development of novel antibody-drug conjugate (ADC) therapies for cancers resistant to current treatments. With this funding, it will begin preparing its pre-clinical program based on a novel target platform, advancing toward IND submission and the development of its first investigational candidates.
Let's advance cancer treatment together
Interested in partnering with us, learning more about our platform, or exploring investment opportunities?
We'd love to hear from you.